Meltrex® – innovative technology of new type of antiretroviral drug production for the treatment of HIV infection

• A.V. Strygin
• O.A. Kozyrev
• B.E. Tolkachev

Abstract

Protease inhibitors and are widely recognised as a potent tool of antiretroviral therapy. Still, many drugs of this group have numerous side effects, which can hinder adherence and therefore promote drug resistance. To improve both adherence and bioavailability there are many novel drug delivery methods. Kaletra®, containing lopinavir/ritonavir is the first co-formulated compound to be tableted by means of melt extrusion. By means of proprietary melt extrusion technology, solid Kaletra® tablets have better solubility and oral bioavailability, compared with the capsule formulation. These tablets require fewer doses each day, and do not need to be taken with food. Therefore this new form helps to achieve a better adherence. Unlike generic drugs, Kaletra® tablets have predictable and stable bioavailability.

Keywords:Кaletra®, melt extrusion, bioavailability, HIV

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)